Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients
<title>Extract</title> Small airways disease is a key feature of chronic obstructive pulmonary disease (COPD) that often precedes emphysema and is the major site of airflow limitation [1]. The prevalence of small airways dysfunction (SAD) ranges from 50–90% and correlates with COPD patient symptoms [2]. SAD is usually well-established before conventional spirometry is abnormal [3], contributes to patient quality-of-life burden [4], and disease exacerbations [5].
Authors
- Sally Meah
- Omar S. Usmani (ORCID: https://orcid.org/0000-0002-4367-254X)
- Vincent Mak (ORCID: https://orcid.org/0000-0002-4690-0819)
- Dimitrios Toumpanakis (ORCID: https://orcid.org/0000-0002-5221-2721)
- Martyn F. Biddiscombe
Institutions
- Imperial College Healthcare NHS Trust (GB)
- National and Kapodistrian University of Athens (GR)
- Charing Cross Hospital (GB)
- Lung Institute (US)
- Imperial College London (GB)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1183/13993003.01326-2025
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00